Aridis Pharmaceuticals Inc. Common Stock
ARDS
ARDS was delisted on the 18th of July, 2023.
16 hedge funds and large institutions have $1.79M invested in Aridis Pharmaceuticals Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 2 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
12% less capital invested
Capital invested by funds: $2.04M → $1.79M (-$251K)
16% less funds holding
Funds holding: 19 → 16 (-3)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EWA
EP Wealth Advisors
Torrance,
California
|
+$77.8K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$54.3K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$40.2K |
| 4 |
State Street
Boston,
Massachusetts
|
+$23.6K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$17.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$12K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$7.92K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$4.72K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$2.72K |
| 5 |
CG
Cutler Group
San Francisco,
California
|
-$1K |
ARDS Hedge Fund Activity: Q3 2022 in Review
16 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Aridis Pharmaceuticals Inc. Common Stock (ARDS) for Q3 2022, worth a combined $1.79M — down 12% from $2.04M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ARDS and 1 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 6 added.
The largest buyer was EP Wealth Advisors, opening a new position worth an estimated $77.8K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $12K sold.
- 16 institutional investors held Aridis Pharmaceuticals Inc. Common Stock (ARDS) as of Q3 2022, down from 19 in Q2 2022.
- Funds reported $1.79M of Aridis Pharmaceuticals Inc. Common Stock stock for Q3 2022, down 12% quarter-over-quarter.
- 1 fund opened new Aridis Pharmaceuticals Inc. Common Stock positions in Q3 2022 and 2 closed out, a net change of -1 holder.
- The largest Aridis Pharmaceuticals Inc. Common Stock buyer in Q3 2022 was EP Wealth Advisors, an estimated $77.8K added.
- The largest Aridis Pharmaceuticals Inc. Common Stock seller in Q3 2022 was Renaissance Technologies, an estimated $12K sold.
Based on aggregated 13F filings for Q3 2022.